In People news

Follow this topic

Bookmark

Record learning outcomes

German healthcare group STADA has appointed Craig Shaw as its new general manager in the UK.

With over 25 years of leadership experience in the health and personal care industry, Shaw has held executive roles at leading organisations including Scholl’s Wellness Company, Reckitt Benckiser, and Novartis Consumer Healthcare. 

Most recently, he served as CEO of Scholl, where he successfully led the transformation of the business into a fully operational stand-alone enterprise.

Peter Goldschmidt, chief executive officer of STADA, commented: “With the UK ranking among STADA’s five largest countries by revenue, accelerating UK growth organically and inorganically is a key strategic priority.

“We are, under Craig’s leadership, embarking on a new chapter of growth in the UK, including by actively seeking attractive acquisition opportunities to strengthen our portfolio and pipeline of consumer healthcare, generics and specialty products.”

Shaw stated: “STADA’s agility and outperformance within the industry have long impressed me. I’m excited to join the team and unlock the full potential of our brands including Nizoral, Zoflora, Cetraben, Covonia, Hedrin, and Savlon. At the same time, we will continue to build momentum in our Specialty portfolio.”

In 2024 the UK accounted for approximately 7 per cent STADA’s global revenues of €4.1 billion. STADA UK supplies a broad range of prescription generic and specialty medicines across therapeutic categories including dermatology, respiratory, oncology and kidney disease.

The UK also forms an essential part of STADA’s global manufacturing and supply network. The Thornton & Ross factory near Huddersfield focuses on liquids and semi-solids such as creams and ointments, producing a diverse range of OTC and prescription products.

Through the Natures Aid facility in Preston, STADA UK also produces and packages a range of herbal medicines and food supplements.